Atlantic Union Bankshares Corp Trims Stock Position in Johnson & Johnson (NYSE:JNJ)

Atlantic Union Bankshares Corp reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 74,689 shares of the company’s stock after selling 1,487 shares during the period. Atlantic Union Bankshares Corp’s holdings in Johnson & Johnson were worth $10,801,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Knuff & Co LLC raised its holdings in shares of Johnson & Johnson by 0.7% in the 3rd quarter. Knuff & Co LLC now owns 9,466 shares of the company’s stock valued at $1,534,000 after acquiring an additional 64 shares in the last quarter. Vertex Planning Partners LLC raised its stake in Johnson & Johnson by 1.3% in the third quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company’s stock valued at $844,000 after purchasing an additional 65 shares in the last quarter. Werba Rubin Papier Wealth Management raised its position in shares of Johnson & Johnson by 3.3% during the 4th quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company’s stock valued at $301,000 after buying an additional 66 shares in the last quarter. Denali Advisors LLC grew its position in Johnson & Johnson by 1.3% in the fourth quarter. Denali Advisors LLC now owns 5,128 shares of the company’s stock worth $742,000 after acquiring an additional 67 shares in the last quarter. Finally, Corepath Wealth Partners LLC increased its stake in Johnson & Johnson by 3.7% in the fourth quarter. Corepath Wealth Partners LLC now owns 1,985 shares of the company’s stock valued at $287,000 after acquiring an additional 70 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.6 %

Shares of NYSE JNJ opened at $166.81 on Friday. The firm has a fifty day simple moving average of $152.95 and a two-hundred day simple moving average of $156.28. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $401.61 billion, a PE ratio of 25.08, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same period last year, the business posted $2.29 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.3% compared to the same quarter last year. Equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 2.97%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Analysts Set New Price Targets

Several equities research analysts have issued reports on JNJ shares. Wells Fargo & Company dropped their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Guggenheim increased their price target on shares of Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a research report on Monday, February 3rd. Raymond James lowered their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 19th. Finally, Bank of America boosted their price target on shares of Johnson & Johnson from $159.00 to $171.00 and gave the stock a “neutral” rating in a research note on Wednesday. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $171.33.

Insider Activity

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.